Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 408

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 408
---
2023                         |     | Registered Offering            |     |            485,391,200 |     |               |     |               |     |  0.0040 |     |                     1,918 |
| At 31 December 2023                      |     |                                |     |          1,189,577,722 |     |     1,000,001 |     | 4,063,321,418 |     |         |     |                           |

| * | Number                                                                                                                                          
 of shares issued includes exercise of pre-funded warrants and Series A, Series B and Series C warrants that were exercisable on an ‘alternative 
 cashless basis’.                                                                                                                                |

| F-70 |

| 22 | Reserves |

The following describes
the nature and purpose of each reserve within equity:

| Schedule of reserves     |                                                                                                                                                                                                      |
| Reserve                  | Description and purpose                                                                                                                                                                              |
| Share capital            | Nominal value of subscribed share capital                                                                                                                                                            |
| Share premium            | Amount subscribed for share capital in excess of nominal value.                                                                                                                                      |
| Merger reserve           | Represents the difference between the fair value and nominal value of shares issued on the acquisition of subsidiary companies where the Company has elected to take advantage of merger accounting. |
| Foreign exchange reserve | Gains/losses arising on retranslating the net assets of overseas operations into sterling                                                                                                            |
| Warrant reserve          | Represents the following:                                                                                                                                                                            
 ·     the                                                                                                                                                                                            
 fair value of warrants denominated in £ at the date of grant. The number and price are fixed at the date of grant. The warrants                                                                      
 expire in November 2025                                                                                                                                                                              
 ·     the                                                                                                                                                                                            
 fair value of pre-funded warrants granted. The pre-funded warrants do not have an expiry date.                                                                                                       
 ·     The                                                                                                                                                                                            
 fair value of Series A, B and C warrants denominated in US$ at the date of grant but allow for the warrants to be exercised on an alternative                                                        
 cashless basis effectively allowing the holders to exercise for nil consideration.                                                                                                                   |
| Accumulated deficit      | All other net gains and losses and transactions with owners (e.g., dividends) not recognised elsewhere.                                                                                              |

| 23 | Retirement benefits |

The Group operates a
defined contribution pension scheme for the benefit of its employees. The assets of the scheme are administered by trustees in funds independent
from those of the Group. The annual charge for the year was £86,000 (2022: £